389 related articles for article (PubMed ID: 17638918)
21. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
Massimino M; Consoli ML; Mesuraca M; Stagno F; Tirrò E; Stella S; Pennisi MS; Romano C; Buffa P; Bond HM; Morrone G; Sciacca L; Di Raimondo F; Manzella L; Vigneri P
Carcinogenesis; 2014 May; 35(5):1132-43. PubMed ID: 24445143
[TBL] [Abstract][Full Text] [Related]
22. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
[TBL] [Abstract][Full Text] [Related]
23. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
Hoover RR; Gerlach MJ; Koh EY; Daley GQ
Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
[TBL] [Abstract][Full Text] [Related]
24. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
25. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
26. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
[TBL] [Abstract][Full Text] [Related]
27. The biology of chronic myelogenous leukemia: implications for imatinib therapy.
Alvarez RH; Kantarjian H; Cortes JE
Semin Hematol; 2007 Jan; 44(1 Suppl 1):S4-14. PubMed ID: 17292736
[TBL] [Abstract][Full Text] [Related]
28. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
29. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
Diaz-Blanco E; Bruns I; Neumann F; Fischer JC; Graef T; Rosskopf M; Brors B; Pechtel S; Bork S; Koch A; Baer A; Rohr UP; Kobbe G; von Haeseler A; Gattermann N; Haas R; Kronenwett R
Leukemia; 2007 Mar; 21(3):494-504. PubMed ID: 17252012
[TBL] [Abstract][Full Text] [Related]
30. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Wang Y; Liu J; Wu Y; Luo W; Lin SH; Lin H; Hawk N; Sun T; Guo JQ; Estrov Z; Talpaz M; Champlin R; Arlinghaus RB
Cancer Res; 2001 Jan; 61(1):138-44. PubMed ID: 11196151
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.
Nakamura S; Yokota D; Tan L; Nagata Y; Takemura T; Hirano I; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
Int J Cancer; 2012 Mar; 130(5):1046-59. PubMed ID: 21400515
[TBL] [Abstract][Full Text] [Related]
32. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
Salesse S; Verfaillie CM
Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
[TBL] [Abstract][Full Text] [Related]
33. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells.
Salesse S; Dylla SJ; Verfaillie CM
Leukemia; 2004 Apr; 18(4):727-33. PubMed ID: 14961028
[TBL] [Abstract][Full Text] [Related]
34. BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells.
Jongen-Lavrencic M; Salesse S; Delwel R; Verfaillie CM
Leukemia; 2005 Mar; 19(3):373-80. PubMed ID: 15674360
[TBL] [Abstract][Full Text] [Related]
35. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG
Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417
[TBL] [Abstract][Full Text] [Related]
36. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.
Yuan H; Wang Z; Li L; Zhang H; Modi H; Horne D; Bhatia R; Chen W
Blood; 2012 Feb; 119(8):1904-14. PubMed ID: 22207735
[TBL] [Abstract][Full Text] [Related]
37. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
MacPartlin M; Smith AM; Druker BJ; Honigberg LA; Deininger MW
Leukemia; 2008 Jul; 22(7):1354-60. PubMed ID: 18548107
[TBL] [Abstract][Full Text] [Related]
38. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.
Holtz MS; Bhatia R
Leuk Lymphoma; 2004 Feb; 45(2):237-45. PubMed ID: 15101707
[TBL] [Abstract][Full Text] [Related]
39. Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib.
Neumann F; Teutsch N; Kliszewski S; Bork S; Steidl U; Brors B; Schimkus N; Roes N; Germing U; Hildebrandt B; Royer-Pokora B; Eils R; Gattermann N; Haas R; Kronenwett R
Leukemia; 2005 Mar; 19(3):458-60. PubMed ID: 15618956
[No Abstract] [Full Text] [Related]
40. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Zhu X; Li Y; Luo X; Fei J
Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]